Critical Contrast: Krystal Biotech (NASDAQ:KRYS) vs. Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences (NASDAQ:GNCA) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

46.1% of Krystal Biotech shares are owned by institutional investors. 2.3% of Genocea Biosciences shares are owned by insiders. Comparatively, 34.3% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Genocea Biosciences and Krystal Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genocea Biosciences N/A -468.08% -93.56%
Krystal Biotech N/A -16.13% -15.55%

Analyst Recommendations

This is a summary of recent recommendations for Genocea Biosciences and Krystal Biotech, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genocea Biosciences 0 0 3 0 3.00
Krystal Biotech 0 0 7 0 3.00

Genocea Biosciences currently has a consensus price target of $5.75, suggesting a potential upside of 62.89%. Krystal Biotech has a consensus price target of $55.20, suggesting a potential upside of 17.45%. Given Genocea Biosciences’ higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than Krystal Biotech.

Risk and Volatility

Genocea Biosciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares Genocea Biosciences and Krystal Biotech’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genocea Biosciences $230,000.00 376.77 -$27.81 million ($3.68) -0.96
Krystal Biotech N/A N/A -$10.89 million ($0.97) -48.45

Krystal Biotech has lower revenue, but higher earnings than Genocea Biosciences. Krystal Biotech is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.


Krystal Biotech beats Genocea Biosciences on 7 of the 11 factors compared between the two stocks.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Krystal Biotech Company Profile

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease. It is also involved in developing KB105 that is in preclinical studies for treating patients with deficient autosomal recessive congenital ichthyosis. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.